Table 3.

Linear regression analysis of factors associated with MMP-9 concentrations

		Simple regression		Multiple regression
Factor	N	Fold difference* (95% CI)	P	Fold difference* (95% CI)	P
Main comparison
No chronic GVHD	29	1.00 (reference)		1.00 (reference)
BOS	33	2.07 (1.37–3.13)	0.001	2.05 (1.37–3.07)	0.001
Non-BOS chronic GVHD	31	1.35 (0.89–2.06)	0.16	1.35 (0.90–2.04)	0.15
Patient age at sample draw, continuous (per decade)	93	0.97 (0.83–1.13)	0.69
Patient sex
Female	41	1.00 (reference)		1.00 (reference)
Male	52	1.52 (1.07–2.16)	0.019	1.50 (1.08–2.09)	0.016
Race
White	80	1.00 (reference)
Others	13	0.69 (0.41–1.14)	0.15
Stem cell source
Peripheral blood stem cell	82	1.00 (reference)
Bone marrow	7	1.33 (0.67–2.62)	0.41
Cord blood	4	0.90 (0.37–2.19)	0 82
Conditioning intensity
Myeloablative	54	1.00 (reference)
Reduced intensity	39	0.76 (0.53–1.09)	0.13
Donor type
HLA-matched relative	37	1.00 (reference)
HLA-mismatched relative	4	0.68 (0.27–1.69)	0.40
Unrelated donor	52	0.92 (0.63–1.33)	0.65
A female donor to a male recipient	23	1.64 (1.10–2.45)	0.016
Prior grade II-IV acute GVHD	57	0.74 (0.52–1.06)	0.10
Duration from HCT to sample draw per year	93	1.14 (1.03–1.27)	0.009
Steroid treatment at sample draw †	53	1.69 (1.19–2.39)	0.003
NIH global severity excluding the lungs ‡
None or mild	32	1.00 (reference)
Moderate	23	1.30 (0.82–2.05)	0.27
Severe	9	0.97 (0.51–1.82)	0.91
Involved sites ‡
Skin	25	0.92 (0.60–1.42)	0.71
Mouth	32	1.15 (0.75–1.75)	0.51
Eye	43	1.18 (1.75–1.84)	0.47
Gastrointestinal tract	10	0.98 (0.55–1.76)	0.95
Liver	5	0.89 (0.41–1.96)	0.78
Joint/fascia	12	1.30 (0.76–2.22)	0.33
Genital	5	1.80 (0.83–3.89)	0.14

^*Fold difference values represent the anti-log₁₀ of the regression coefficient.

^†One patient is excluded due to absence of information.

^‡Analysis was performed in 64 patients with BOS or non-BOS chronic GVHD.